We compared the responses to olaparib (log2-fold change in cell abundance) with baseline gene expression data from 22 BRCA1/2 WT breast cancer cell lines using PRISM Repurposing screen data from the DepMap portal [29]. The gene discussed is BRCA1; the disease is breast carcinoma.